Acorda Therapeutics Sees Improvements In Phase 2b Clinical Study Of CVT301

Acorda Therapeutics Inc (NASDAQ: ACOR) disclosed that data from the Phase 2b Clinical trial of CVT-301, which was published and reviewed journal Movement Disorders, indicated that there was significant improvement in motor function. The company tried it with those people having Parkinson's disease and treated with CVT-301 compared to the placebo.Accorda Therapeutics said that a treatment impact was evident within ten minutes of dosing and sustained for a minimum of one hour, which was the longest time point at which patients were assessed. Henry Hospital Director of the PD and Movement Disorders Program and lead author of the study, Peter LeWitt, said that "Oral levodopa is a cornerstone of Parkinson's disease treatment, but after chronic therapy, approximately half of people with PD who are treated with oral L-dopa experience OFF periods. OFF periods tend to increase in frequency, severity and duration during the course of the disease, and are among the most challenging experiences for people with this disorder."He continued, "Based on the data from this Phase 2b clinical study, CVT-301 has the potential to restore motor function to people with Parkinson's disease when they experience OFF periods, and this is now being studied in a Phase 3 clinical trial."The company stated that the Phase 2b trial was a randomized, double blind, placebo-controlled, multicenter trial in 86 people with PD for the treatment of OFF periods. The company added that participants were randomized to self-administer CVT-301 or placebo to the lung via an inhaler, as an adjunct to their established oral PD medications. They were given 35mg of CVT-301 or placebo in study weeks 1 and 2, and 50mg of drug or placebo in weeks 3 and 4.On Tuesday, the stock shed 0.73%.